TScan reports preliminary Phase 1 data for TSC-100/101; TSC-101 advances to Dose Level 2

TScan Therapeutics, Inc.

TSC-101 in high-risk MDS patient: 100% donor chimerism, no p53 mutation detected (sensitivity 0.01%), no DLTs.
TSC-100 in T-cell ALL patient showed T cell expansion with activation markers on Day 7 post-infusion.
Study advancing TSC-101 to Dose Level 2; RP2D and interim data expected by end of 2023.
Two control patients with MDS had incomplete donor chimerism; one in early relapse.
Phase 1 trial design includes three dose levels; second dose at DL2 and DL3 for both candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.